The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 39, Issue 3, 2014, Pages 173-181

  Miller, Bruce E ^a   Smart, Kevin ^b   Mistry, Sunil ^b   Ambery, Claire L ^b   Bloomer, Jackie C ^b   Connolly, Paul ^b   Sanderson, Dominic ^b   Shreeves, Trevor ^b   Smith, Rachel ^b   Lazaar, Aili L ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bioavailability; Chemokine receptor antagonist; Chronic obstructive pulmonary disease; Danirixin; GSK1325756; Safety

Indexed keywords

DANIRIXIN; OMEPRAZOLE; PIPERIDINE DERIVATIVE; PROTON PUMP INHIBITOR; RESPIRATORY TRACT AGENT; SULFONE; TABLET;

AGE; AGED; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG INTERACTION; ENGLAND; FEMALE; HUMAN; MALE; MEDICINAL CHEMISTRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PH; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SOLUBILITY; TABLET;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENGLAND; FASTING; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; PIPERIDINES; POSTPRANDIAL PERIOD; PROTON PUMP INHIBITORS; RESPIRATORY SYSTEM AGENTS; SOLUBILITY; SULFONES; TABLETS;

EID: 84893186080     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-014-0179-8     Document Type: Article

References (19)

1. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH (1997) The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 19:1013-1023
2. Blume H, Donath F, Warnke A, Schug BS (2006) Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29:769-784
3. Bor S, Kitapcioglu B, Solak ZA, Ertilav M, Erdinc M (2010) Prevalence of gastroesophageal reflux disease in patients with asthma and chronic obstructive pulmonary disease. J Gastroenterol Hepatol 25:309-313
4. Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MR, Holden SN, Benet LZ, Ware JA (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92:203-213
5. Chapman RW, Phillipsa JE, Hipkina RW, Currana AK, Lundella D, Fine JS (2009) CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121:55-68
6. GSK (2013a) GSK Study CX3112483 (NCT01209052). A single-centre, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single, oral, ascending doses and repeat oral doses of GSK1325756 in healthy male subjects. Results summary available at: http://www.gsk-clinicalstudyregister.com. Last accessed 07 June 2013
7. GSK (2013b) GSK Study CX3113722 (NCT01209104). A single-dose, open, randomized, crossover investigation of age, gender, food-effect and proton-pump inhibitor interaction on the pharmacokinetics of GSK1325756 in healthy adult subjects and a single-dose, double blind, parallel-group, placebo-controlled investigation of the pharmacokinetics of GSK1325756 in healthy elderly adult subjects. Results summary available at: http://www.gsk-clinicalstudyregister.com. Last accessed 07 June 2013
8. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H (2010) SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 35:564-570
9. International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf; 1996. Last accessed: April 24, 2013
10. Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R (2011) SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 72:282-293
11. Mukaida N (2003) Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 284:L566-L577
12. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42:1087-1103
13. Quint JK, Wedzicha JA (2007) The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 119:1065-1071
14. Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Strysak P, Rosenberg E, Staudinger H (2013) CXCR2 antagonist MK-7123 - a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187:A6071
15. Russell TL, Berardi RR, Barnett JL, Dermentzoglou LC, Jarvenpaa KM, Schmaltz SP, Dressman JB (1993) Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm Res 10:187-196
16. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951
17. Spooner N, Lad R, Barfied M (2009) Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal Chem 81:1557-1563
18. Stockley RA (2002) Neutrophils and the pathogenesis of COPD. Chest 121:151S-155S
19. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul; 2008. http://www.wma.net/en/30publications/10policies/b3/index.html. Date last updated: October 2008. Last accessed: 22 April 2013